Industry Overview

US myocardial infarction (MI) market was valued at $3.3 billion in 2025 and is projected to reach $5.8 billion by 2035, registering a CAGR of 5.8% during the forecast period. Growth is largely driven by the rising prevalence of cardiovascular diseases, along with continuous advancements in interventional cardiology and increasing demand for early diagnosis and effective treatment options. Innovations in drug-eluting stents, imaging catheters, and minimally invasive surgical techniques are significantly improving clinical outcomes and patient recovery. Additionally, the growing geriatric population and the increasing incidence of lifestyle-related conditions such as obesity, diabetes, and hypertension are contributing to a higher burden of myocardial infarction cases. The expansion of emergency medical services and specialized cardiac care centers across the US is further enhancing access to timely treatment, thereby increasing procedural volumes and supporting overall market growth.

Recent developments highlight a strong focus on prevention, awareness, and advanced treatment solutions. In April 2026, Abbott Laboratories published survey findings indicating that while 74% of US adults believe chronic diseases, including cardiovascular conditions, are preventable, only a quarter feel confident in managing their health. This reflects a gap in awareness and education, emphasizing the need for better preventive strategies. Furthermore, in December 2025, Philips announced the acquisition of SpectraWAVE to strengthen its coronary intervention portfolio. The deal includes AI-powered intravascular imaging and physiological assessment technologies designed to improve diagnosis and treatment of coronary artery disease. These innovations support better clinical decision-making during procedures like PCI, which are critical in managing myocardial infarction. The development highlights growing adoption of advanced imaging solutions in the US cardiovascular care market.

Market Dynamics

Interventional Procedures Leading Revenue Generation

Interventional procedures continue to dominate the US myocardial infarction (MI) market, driven by the high volume of percutaneous coronary intervention (PCI) procedures performed in acute cases, especially ST-elevation myocardial infarction (STEMI), where rapid revascularization is essential. The increasing adoption of advanced technologies such as drug-eluting stents and imaging-guided PCI tools is significantly contributing to segment growth by improving procedural precision and patient outcomes. In March 2026, Medtronic announced its support for the EMBRACE clinical study, which evaluates renal denervation technology in high-risk cardiovascular patients undergoing PCI. The study is designed to assess outcomes including myocardial infarction and other major adverse cardiac events across a large patient population. It also focuses on better management of uncontrolled hypertension, a major contributor to recurrent heart attacks. Such initiatives reflect the growing emphasis on combining interventional procedures with preventive strategies. Overall, these advancements highlight continuous innovation aimed at enhancing treatment effectiveness and reducing long-term cardiovascular risk in the US MI market.

Pharmacological Treatment Supporting Long-Term Care

Pharmacological treatment plays a crucial role in the management of myocardial infarction, particularly for patients with non-ST-elevation myocardial infarction (NSTEMI), where long-term use of antiplatelets, anticoagulants, and statins is essential to prevent recurrence and improve outcomes. Growing adherence to guideline-based therapies is contributing to consistent revenue growth in this segment. In April 2026, Abbott Laboratories released survey findings showing that 74% of US adults believe chronic diseases, including cardiovascular conditions, are preventable. However, only one in four individuals reported confidence in their ability to effectively manage their health. The study further highlighted that rising healthcare costs, lack of clear information, and confusion around disease management act as major barriers to preventive care. These insights emphasize the need for stronger patient education and improved access to treatment, which are critical for enhancing long-term pharmacological management and reducing the risk of myocardial infarction.

Market Segmentation

• Baed on treatment type, the market is segmented into pharmacological treatment, interventional treatment, and diagnostics.
• Based on device type, the market is segmented into coronary stents, catheters & guidewires, thrombectomy devices, and imaging catheters (IVUS, OCT).
• Based on end-user, the market is segmented into hospitals, cardiac care centers/cath labs, and emergency medical services (EMS).

Diagnostic & Monitoring Enhancing Early Detection

Diagnostic tools such as ECG and troponin testing play a critical role in the early detection of myocardial infarction, enabling rapid clinical decision-making. Ongoing advancements in biomarker sensitivity and imaging technologies are further enhancing diagnostic accuracy and supporting timely interventions. In April 2026, Medtronic completed the $585 million acquisition of CathWorks to expand its cardiovascular capabilities. This acquisition includes the AI-powered FFRangio system, which is already commercially available in the US and allows non-invasive evaluation of coronary artery disease. The technology helps clinicians make more precise and informed treatment decisions. By improving diagnostic efficiency, it has the potential to reduce major adverse cardiac events, including myocardial infarction. Overall, the development reflects a growing emphasis on advanced, data-driven solutions in cardiac care. It also highlights continued innovation aimed at improving patient outcomes in the US myocardial infarction market.

Market Players Outlook

The major companies operating in the US myocardial infarction market include Cardinal Health, Johnson & Johnson, Roche, Pfizer, and Merck & Co., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In December 2025, Siemens Healthineers introduced the syngo.CT Coronary Cockpit, an AI-powered imaging software designed to enhance the diagnosis and management of coronary artery disease. The solution enables automated plaque analysis and improved treatment planning using coronary CT angiography, supporting early detection of cardiovascular risks. By improving clinical decision-making and reducing unnecessary invasive procedures, the innovation is expected to strengthen MI prevention and diagnostic pathways in the US healthcare market.

• In September 2025, Roche announced results from its global TSIX study evaluating a sixth-generation high-sensitivity Troponin T test for diagnosing myocardial infarction. The study demonstrated enhanced accuracy and faster identification of heart attacks, supporting efficient patient triage in emergency settings. With validation across diverse populations, including the US, the innovation is expected to improve early diagnosis and clinical outcomes. This advancement highlights ongoing progress in diagnostic technologies within the US MI market.

• In August 2025, Medtronic received FDA approval for expanded use of its Evolut TAVR systems for redo transcatheter aortic valve procedures in high-risk patients. The approval is supported by ongoing studies such as RESTORE, aimed at evaluating safety and performance outcomes. As TAVR procedures are widely used in US cardiac care, this advancement may help reduce complications associated with severe heart conditions, including risks linked to myocardial infarction.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Key companies operating in the US myocardial infarction market
• Based on the availability of data, information related to new protections and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.